Form 4: FibroGen CEO Increases Stake with Stock Purchases

FibroGen CEO Thane Wettig acquired additional common stock in two separate transactions in November 2025, signaling increased confidence.

Summary

• Thane Wettig, the Chief Executive Officer and a Director of FibroGen Inc. (FGEN), acquired additional shares of the company's common stock.
• On November 13, 2025, Wettig purchased 1,000 shares of common stock at a price of $9.18 per share.
• On November 17, 2025, Wettig purchased an additional 2,700 shares of common stock at a price of $9.0999 per share.
• Following these transactions, Wettig's direct beneficial ownership of common stock increased to 24,939 shares.
• An additional 40 shares are indirectly beneficially owned by Wettig's spouse.

Sentiment

Score: 7

Explanation: The CEO's personal investment in the company's stock is generally viewed as a positive signal of confidence in the company's future performance and valuation.

Positives

• CEO Thane Wettig increased his direct beneficial ownership in FibroGen Inc. by 3,700 shares, demonstrating management's confidence in the company's future prospects.
• The purchases were made at market prices, indicating a personal investment decision rather than a compensatory grant.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may interpret the CEO's increased stake as a positive indicator of management's belief in the company's value and future growth, potentially boosting investor confidence.

Key Dates

Keywords

FibroGen, FGEN, insider buying, stock purchase, CEO, director, common stock, beneficial ownership